# Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)

> **NCT01830959** · PHASE4 · UNKNOWN · sponsor: **University of Cincinnati** · enrollment: 50 (estimated)

## Conditions studied

- Sarcoidosis

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01830959
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2015-12-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01830959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01830959, "Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01830959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*